SYRE Spyre Therapeutics reports narrower Q4 2025 pershare loss than consensus forecasts with shares edging higher in todays trading Limbach Holdings LMB Stock Pricing Evaluation Q4 2025 Profit Disappoints Texas Instruments Incorporated TXN Secures Broad Analyst Upgrades Following Q1 2026 Earnings Beat and Rosy Forward Guidance